
Sign up to save your podcasts
Or


Changsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously treated advanced gastric or gastro-oesophageal junction cancer.
Read the full article:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lancet
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
By The Lancet GroupChangsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously treated advanced gastric or gastro-oesophageal junction cancer.
Read the full article:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lancet
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

322 Listeners

112,454 Listeners

22 Listeners

22 Listeners

0 Listeners

0 Listeners

2 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

1 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners